Efficacy and safety of gestogens in women with metabolic syndrome

Abstract

The paper presents a study of the safety and effectiveness of gestogen support of pregnancy in patients with metabolic syndrome. Efficacy of dydrogesterone in the development of the threat of termination in the first trimester has been demonstrated in 91% of patients with metabolic syndrome. Dydrogesterone use safety has been proven on the basis of no change in terms of the hemostatic system and components of lipid and carbohydrate metabolism.

Keywords

• pregnancy
• metabolic syndrome
• threatened miscarriage
• dydrogesterone
• insulin resistance